Braveheart Bio reported positive results from an open-label randomized phase II dose-ranging study of BHB-1893 (HRS-1893) in obstructive hypertrophic cardiomyopathy. Results presented at the American College of Cardiology’s Annual Scientific Session showed rapid and substantial reductions in left ventricular outflow tract gradient, the study’s primary endpoint. The dataset supports Braveheart’s continued development strategy for cardiac myosin inhibition in a high-unmet-need cardiomyopathy segment where durable hemodynamic improvement is closely tied to clinical value. For the market, phase II success in an electrophysiology-adjacent cardiovascular mechanism can affect partnership and financing dynamics by strengthening the probability of advancing into larger pivotal programs.